3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
27
Leukemia, Myeloid, Acute
27
Leukemia
16
Myelodysplastic Syndromes
13
Myeloproliferative Disorders
4
Myelodysplastic-Myeloproliferative Diseases
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Leukemia, Erythroblastic, Acute
4
Hematologic Neoplasms
4
Congenital Abnormalities
4
Leukemia, Myelomonocytic, Chronic
3
Anemia, Refractory, with Excess of Blasts
3
Primary Myelofibrosis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Blast Crisis
2
Thrombocytosis
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neutropenia
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Interventions
Cyclophosphamide
13
fludarabine
11
Mycophenolic Acid
9
Busulfan
8
fludarabine phosphate
7
Tacrolimus
7
pirtobrutinib
6
Whole-Body Irradiation
6
Rituximab
6
Melphalan
6
Imatinib Mesylate
5
Bone Marrow Transplantation
5
ponatinib
4
Mesna
4
Granulocyte Colony-Stimulating Factor
4
Azacitidine
4
venetoclax
3
nilotinib
3
lintuzumab
3
Stem Cell Transplantation
3
Sirolimus
3
Platelet Transfusion
3
Methotrexate
3
Cytarabine
3
Cyclosporine
3
Alemtuzumab
3
vosaroxin
2
ruxolitinib
2
ibrutinib
2
Thiotepa
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
Tretinoin
×
Other hematologic neoplasm
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled